Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 551 - 600 out of 97,147

Document Document Title
WO/2014/076235A1
The present invention relates to a composition for treating Fragile X syndrome in a subject in need thereof, wherein said composition comprises an effective amount of a modulator of a chloride transporter.  
WO/2014/078394A1
The current invention offers a method of treatment of aggression in a human subject suffering from ADHD, comprising: (a) determining the weight of the human subject; (b) calculating a dose of molindone such to achieve a plasma concentrat...  
WO/2014/078372A1
Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R1, R2, Ra, Rb, Rc, Rd, X, Ring B, and Ring C are as defined herein, and wherein Ring B moiety and the NH-C...  
WO/2014/076643A1
A compound particularly for treating depression and anxiety, characterized in that it comprises the combination of at least 11 -keto-beta- boswellic acid (KBA) and acetyl-11-keto-beta-boswellic acid (AKBA). The patent also relates to the...  
WO/2014/075629A1
A method of extracting neural stem cells from a living subject, comprising the steps of introducing magnetic nanoparticles into the subject, targeting the neural stem cells with the magnetic nanoparticles to form magnetic nanoparticle-ta...  
WO/2014/075146A1
The present invention relates to novel macrocyclic compounds of Formula I and their use as novel therapeutic agents for example as novel compounds used in methods of preventing and/or treating a disease, condition or state in a subject a...  
WO/2014/074381A1
The subject invention provides a Laquinimod amine salt, which is laquinimod meglumine, laquinimod choline hydroxide, laquinimod L-lysine or laquinimod monoethanolamine.  
WO/2014/073889A1
The present invention relates to a solid dispersion characterized in that it comprises carbamic acid 3-(4-benzyloxy-phenyl)-isoxazol-5-ylmethyl ester as an active ingredient and a water-soluble polymer having a glass transition temperatu...  
WO/2014/071507A1
The disclosure provides compositions containing preparations from plants of the family Marcgraviaceae and from plants of the family Platanaceae. The disclosure also provides methods and uses of plant preparations for treating anxiety, st...  
WO/2014/073450A1
The present invention addresses the problem of providing a drunkenness-relieving agent which can relieve the severity of a badly or heavily drunk state in heavy alcohol use. The means for solving the problem is the use of an insoluble co...  
WO/2014/074795A1
The present invention provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working densi...  
WO/2014/072261A1
The present invention relates to compounds of formula (I) and its use for the treatment of neurological disorders.  
WO/2014/072881A1
The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof and N-oxides thereof; processes and intermediates for preparation of; and compositions and uses thereof. The present invention...  
WO/2014/071449A1
The present disclosure teaches generally neuroprotection and in particular the use of non-hormonal neuroactive steroids to ameliorate inflammation of the central nervous system (CNS). More specifically, the present claims define methods ...  
WO/2014/072957A1
Disclosed is a compound of formula (I), wherein R1, R2, R3, R4, R5 and m are as described herein, as a modulator of nicotinic acetylcholine receptors particularly α7 subtype, its tautomeric forms, its stereoisomers, its pharmaceutically...  
WO/2014/073946A3
The invention relates to the use of betanidine and its derivatives, betalains and their derivatives, betalamic acid and its derivatives, including the spatial configurations thereof, for the production of a drug for the treatment, preven...  
WO/2014/074976A1
Provided are compounds for the treatment of neurological diseases or injuries, including neurodegenerative diseases, stroke, trauma, epilepsy, acute and chronic kidney injuries, diabetes mellitus, and/or seizures. In some embodiments, de...  
WO/2014/072498A1
The present invention relates to 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carboni trile derivatives having pharmacological activity formula (I) to processes of preparation of such compounds, to pharmaceutical compositions com...  
WO/2014/074592A1
The instant invention relates to seaweed extract compositions, processes for isolation, isolated active agents, and methods of treating disease, disorders and conditions in a subject, including, reactive oxygen species (ROS)- mediated di...  
WO/2014/071371A1
Disclosed herein are cocrystals of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, which is a prodrug of methyl hydrogen fumarate  
WO/2014/069667A1
An objection of the present invention is to provide an agent for preventing or improving decline in brain function such as decreased perception ability, decreased memory learning ability, decreased thinking ability, decreased concentrati...  
WO/2014/068988A1
The present invention relates to pyrazolopyridine derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which v...  
WO/2014/071134A1
In certain embodiments, the disclosure relates to 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, such as those described by formula provided herein, pharmaceutical compositions, and methods related thereto. In certain embod...  
WO/2014/068372A1
The present invention relates to a pharmaceutical composition of tapentadol for parenteral administration which provides prolonged release of tapentadol. Present invention also relates to the process of preparation of pharmaceutical comp...  
WO/2014/071042A1
The present invention provides, inter alia, methods for identifying a candidate agent that may be effective to treat or ameliorate an effect of a neurodegenerative disease in a subject. These methods include: (a) contacting a wildtype ne...  
WO/2014/069626A1
Provided is a method for producing a compound represented by formula (I) (wherein R1 and R2 may be the same or different and each represents a hydrogen atom or the like, and Z represents an optionally substituted aryl group or the like) ...  
WO/2014/070038A1
The invention relates to the pharmaceutical industry and the field of medicine and can be used in the creation and administration of solid dosage forms having neuroprotective, antiamnesic, antioxidant, antihypoxic and anti-ischemic activ...  
WO/2014/071219A1
The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfec...  
WO/2014/067281A1
Disclosed is a tapentadol hydrochloride crystalline form C having high stability and having characteristic peaks at 14.627 (100%), 15.476 (20.7%), 16.710 (33.7%), 18.999 (48.3%), 20.479 (80.7%), 21.790 (27.9%), 25.110 (35.2%), 25.911 (36...  
WO/2014/071044A1
The invention relates to compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein R', R1 through R7 and Ar are as defined herein. These compounds are useful as inhibitors of phosphodiesterase 10 (PDE10A) which are ...  
WO/2014/067038A1
Disclosed are target points for treating human ADSL deficiency, the target points comprising PAICS gene, mRNA of PAICS gene or PAICS protein. Use of PAICS gene, mRNA of PAICS gene or PAICS protein for treating human ADSL deficiency is al...  
WO/2014/068499A1
This invention relates to a method of increasing a feeling of a) energy or b) cognitive functions, selected from the group consisting of: sustained attention, faster reaction times, and information processing; or c) quality of sleep; or ...  
WO/2014/067505A2
The invention relates to peptides which bind to amino-terminal truncated pEAβ3-42, the free glutamic acid group of which lies in position 3 or 11 in the form of cyclized pyroglutamate. Four oligopeptides were identified using mirror ima...  
WO/2014/069666A1
An objection of the present invention is to provide an agent for preventing or improving decline in brain function such as decreased perception ability, decreased memory learning ability, decreased thinking ability, decreased concentrati...  
WO/2014/071194A2  
WO/2014/070745A1
Solid forms of certain opioid agonists are provided herein. Methods of preparing the solid forms, methods of using the solid forms, and pharmaceutical compositions comprising the solid forms are also provided herein.  
WO/2014/069434A1
[Problem] To provide a novel thiazolidinone derivative. [Solution] A thiazolidinone derivative or a pharmaceutically acceptable salt thereof represented by formula (I) or (II). (I) (II)  
WO/2014/068171A1
Compounds of formula I or formula II, wherein Q1Q3 and R1-R5 are as defined in the claims, exhibit CytC derived peroxidase inhibiting activity and are thus useful as CytC derived peroxidase inhibiting agents.  
WO/2014/068327A3
The present invention relates to the use of agents (including heparin derivatives) for the prevention and/or treatment of CNS damage.  
WO/2014/071157A1
The invention provides compositions and in vivo, ex vivo and in vitro methods for trans-differentiation of or re-programming mammalian cells to functional neurons. In particular, the invention provides methods for engineering non-neurona...  
WO/2014/071005A1
Described herein are compositions and methods for treating or preventing ischemic injury. In particular, the methods and compositions relate to the use of a neuroprotective steroid, such as a progestogen, such as progesterone or allopreg...  
WO/2014/071282A1
This disclosure relates to methods for improving neural function in a mammal with a proteinopathy comprising administering a therapeutically effective amount of an agent that increases glucocerebrosidase activity in the mammal. Also disc...  
WO/2014/065434A1
The present invention provides a compound which has an effect of inhibiting amyloid beta production, especially an effect of inhibiting BACE1, and which is useful as a therapeutic or prophylactic agent for diseases induced by production,...  
WO/2014/066659A1
The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of disease.  
WO/2014/066304A1
Disclosed herein are compounds, compositions, formulations, kits and methods of treatment useful for treating or preventing one or more hyperproliferative disorders, e.g., cancer or a neurological disease or disorder.  
WO/2014/064715A3
The present invention relates to an amorphous form of vilazodone hydrochloride and processes for its preparation. Amorphous vilazodone hydrochloride is prepared by ball milling sieved vilazodone hydrochloride. Further provided are proces...  
WO/2014/064257A1
The invention provides a conjugate comprising(i) a selectivity agent which binds specifically to one or more neurotransmitter transporters selected from the group consisting of a dopamine transporter (DAT), serotonine transporter (SERT) ...  
WO/2014/065194A1
Provided are a nerve growth inhibitor and a cutaneous-sensory-irritation inhibitor, with which cutaneous-sensory irritation and nerve growth based on newly found nerve growth mechanisms can be effectively inhibited. This nerve growth inh...  
WO/2014/064028A1
This invention relates to a new medical use for certain chemical compounds and pharmaceutical compositions containing them. The invention relates to compounds which are mGlu2/3 negative allosteric modulators for use in the treatment of A...  
WO/2014/064131A3
This application discloses compounds according to generic Formula I wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases as...  

Matches 551 - 600 out of 97,147